Although TGFβ inhibition alone is not a good strategy for cancer treatment, targeting TGFβ signaling may increase the efficacy of chemotherapeutic agents by normalizing the ECM and tumor blood vessels, suppressing EMT, and eliminating CSCs. This evidence concerns the gene TGFB1 and cancer.